Hongmei Wang

Ms. Hongmei Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YWYuanli Wu
Yuanli Wu
JZJing Zhang
Jing Zhang
WZWeiying Zhou
Weiying Zhou
ZYZhongzhen Yuan
Zhongzhen Yuan
HWHongmei Wang
Hongmei Wang
Background: This study aimed to identify shared and distinct prognostic factors related to organ-specific metastases (liver, lung, bone, and brain) in extensive-stage small cell lung cancer (ES-SCLC) patients, then construct nomograms for survival prediction. Methods: Patient data for ES-SCLC were from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2019. Kaplan–Meier analysis was applied to estimate overall survival (OS), and Cox regression was used to identify prognostic factors. A Venn diagram was utilized to distinguish common and unique prognostic factors among the variables assessed. These identified prognostic factors were used to formulate a nomogram, and its predictive accuracy and reliability were evaluated using C-indexes, calibration curves, and receiver operating characteristic (ROC) curves. Results: A total of 24,507 patients diagnosed with ES-SCLC exhibiting metastases to the liver, lung, bone, and brain were included. The 6-month, 1-year, and 2-year OS rates were 46.1%, 19.7%, and 5.0%, respectively. Patients with liver metastasis demonstrated the most unfavorable prognosis, with a 1-year OS rate of 14.5%, while those with brain metastasis had a significantly better prognosis with a 1-year OS rate of 21.6%. The study identified seven common factors associated with a poor prognosis in ES-SCLC patients with organ-specific metastases: older age, male sex, unmarried status, higher T stage, presence of other metastases, and combination radiotherapy and chemotherapy. Furthermore, specific prognostic factors were identified for patients with metastasis to the liver, bone, and brain, including paired tumors, lack of surgical treatment at the primary site, and household income, respectively. To facilitate prognostic predictions, four nomograms were developed and subsequently validated. The performance of these nomograms was assessed using calibration curves, C-indexes, and the area under the curve (AUC), all of which consistently indicated good predictive accuracy and reliability. Conclusions: Patients diagnosed with ES-SCLC with organ-specific metastases revealed shared and distinct prognostic factors. The nomograms developed from these factors demonstrated good performance and can serve valuable clinical tools to predict the prognosis of ES-SCLC patients with organ-specific metastases.

27 January 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
TLTianwen Luo
Tianwen Luo
YWYutong Wang
Yutong Wang
XSXuefeng Shan
Xuefeng Shan
YBYe Bai
Ye Bai
CHChun Huang
Chun Huang
HWHongmei Wang
Hongmei Wang
Background: The identification of the homogeneous and heterogeneous risk factors for different types of metastases in colorectal cancer (CRC) may shed light on the aetiology and help individualize prophylactic treatment. The present study characterized the incidence differences and identified the homogeneous and heterogeneous risk factors associated with distant metastases in CRC. Methods: CRC patients registered in the SEER database between 2010 and 2016 were included in this study. Logistic regression was used to analyse homogeneous and heterogeneous risk factors for the occurrence of different types of metastases. Nomograms were constructed to predict the risk for developing metastases, and the performance was quantitatively assessed using the receiver operating characteristics (ROC) curve and calibration curve. Results: A total of 204,595 eligible CRC patients were included in our study, and 17.07% of them had distant metastases. The overall incidences of liver metastases, lung metastases, bone metastases, and brain metastases were 15.34%, 5.22%, 1.26%, and 0.29%, respectively. The incidence of distant metastases differed by age, gender, and the original CRC sites. Poorly differentiated grade, more lymphatic metastasis, higher carcinoembryonic antigen (CEA), and different metastatic organs were all positively associated with four patterns of metastases. In contrast, age, sex, race, insurance status, position, and T stage were heterogeneously associated with metastases. The calibration and ROC curves exhibited good performance for predicting distant metastases. Conclusions: The incidence of distant metastases in CRC exhibited distinct differences, and the patients had homogeneous and heterogeneous associated risk factors. Although limited risk factors were included in the present study, the established nomogram showed good prediction performance.

28 April 2023 in Drug Development Research
Verified
Journal Article
Closed access
HWHongmei Wang
Hongmei Wang
XSXuefeng Shan
Xuefeng Shan
YPYang Peng
Yang Peng
WZWeiying Zhou
Weiying Zhou

9 November 2021 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
HWHongmei Wang
Hongmei Wang
CHChun Huang
Chun Huang
YYYang Yang
Yang Yang
LKLingxi Kong
Lingxi Kong
XZXiaoying Zheng
Xiaoying Zheng
XSXuefeng Shan
Xuefeng Shan

3 June 2026 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
YYYang Yang
Yang Yang
ZXZeJie Xu
ZeJie Xu
YPYu Peilin
Yu Peilin
HLHaidong Li
Haidong Li
HWHongmei Wang
Hongmei Wang
XSXuefeng Shan
Xuefeng Shan
Hospitalized patients with heart failure (HF) frequently receive multiple high-risk intravenous (IV) medications, placing them at a substantial risk of clinically significant drug-related problems (DRPs). Timely severity-based stratification of IV medication-related risks remains challenging, particularly in the context of complex regimens and organ dysfunction. To develop and externally validate a clinically applicable machine learning-based stratification tool for classifying IV medication-related risk severity in hospitalized patients with HF and to support pharmacist-led medication safety management through a web-based clinical decision support tool. This multicenter retrospective study included 1,884 adult patients hospitalized with HF from seven tertiary hospitals, with an independent external validation cohort of 100 patients. IV medication-related DRPs were identified and classified by senior clinical pharmacists using the Pharmaceutical Care Network Europe (PCNE) DRP classification (version 9.1) and stratified by severity using the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) index. Medication risk severity (levels C-F) was used as a multiclass stratification outcome. Candidate clinical and medication-related variables reflecting patient characteristics, organ function, and medication burden were selected using least absolute shrinkage and selection operator (LASSO) regression, and six machine learning algorithms for multiclass risk stratification were developed and compared. Overall, 1405 patients (74.6%) experienced at least one IV medication-related DRP, with treatment safety problems predominating. Eleven clinically interpretable predictors, including neutrophil percentage, fibrinogen, serum albumin, and creatinine clearance were retained in the final models. In internal validation, the random forest (RF) model achieved the highest discriminative performance (AUC = 0.934), whereas in external validation, the artificial neural network (ANN) demonstrated the best performance (AUC = 0.921). Considering its consistent performance across datasets, ANN was selected as the final model, achieving AUC of 0.889 and 0.921 in the internal and external validation, respectively. Based on this model, a web-based clinical decision support tool was developed to provide individualized IV medication risk stratification at the point-of-care. A machine learning-based clinical decision support tool that incorporates routinely available clinical and medication-related variables can accurately stratify IV medication-related risk severity in hospitalized patients with HF.

4 November 2026 in Oncology Letters
Verified
Journal Article
Open access
PDF file
JMJingxin Mao
Jingxin Mao
YLYang Liu
Yang Liu
MLMengqian Li
Mengqian Li
QHQing Hu
Qing Hu
HWHongmei Wang
Hongmei Wang
The present study aimed to systematically review the anticancer chemical constituents, pharmacological effects, and molecular targets of Carpesium cernuum L., clarify the molecular network of its anticancer mechanisms, summarize the research achievements and limitations and provide a scientific reference for its development and utilization, the research and development of novel anticancer drugs, and clinical applications. Through literature collation and experimental data integration, the chemical constituents of C. cernuum were classified and identified, and with the aid of in vitro cell experiments, partial in vivo animal experiments and molecular biology techniques, the anticancer effects of its extracts and active constituents as well as the key signaling pathways were investigated. Notably, all included evidence was strictly stratified by research type (crude extract/fraction/isolated monomer, in vitro cell model/in vivo animal model/network pharmacology prediction) to clarify the evidence level of each anticancer claim. A total of 109 compounds were isolated and identified from C. cernuum, among which 60 sesquiterpenoids were the major components. Its active constituents exhibited promising inhibitory effects in preclinical studies against multiple cancers including prostate cancer, pancreatic cancer, leukemia and breast cancer. Existing anticancer evidence was predominantly derived from in vitro cell‑based assays, with a small number of in vivo animal validations and preliminary network pharmacology predictions; high‑level clinical evidence is still vacant. By regulating signaling pathways such as phosphatidylinositol 3‑kinase (PI3K)/Akt/mTOR and Hippo, they exert multi‑dimensional anticancer effects, including cell proliferation inhibition, apoptosis induction, and metastasis suppression. In vitro and partial in vivo preclinical evidence indicates that the active ingredients of C. cernuum exert potential inhibitory effects against various tumors such as prostate cancer and pancreatic cancer. By targeting key signaling pathways including PI3K/Akt/mTOR and Hippo, it achieves multi‑modal anticancer effects such as proliferation inhibition and apoptosis induction, showing favorable preliminary biocompatibility in existing preclinical experiments. However, the current research has limitations including insufficient in vivo verification, uneven evidence quality, and lack of standardized dose‑effect data, which restrict clinical transformation. Collectively, C. cernuum and its bio‑active metabolites display pre‑clinical antitumor potential, yet further pharmacological validation and translational investigations are required to evaluate clinical applicability